DTIC-Dome

(Dacarbazine)

ApprovedSmall molecule

Dacarbazine is a chemotherapy drug used to treat certain cancers, including melanoma and lymphomas. It works by damaging cancer cells' DNA to stop them from growing and dividing.[2] DTIC-Dome is currently approved and in use across 20 indications[4].[1]

DTIC-Dome is one of 364 small molecule programs targeting Uterine Leiomyosarcoma. It is currently in Approved.

Indications

146

Total Trials

Active Trials

363

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Uterine LeiomyosarcomaActive, not recruiting

LeiomyosarcomaActive, not recruiting

LymphomaApproved

Cutaneous MelanomaActive, not recruiting

Pancreatic Neuroendocrine TumorApproved

Metastatic MelanomaActive, not recruiting

Hodgkins LymphomaActive, not recruiting

NeuroblastomaActive, not recruiting

Uveal MelanomaActive, not recruiting

Classic Hodgkin LymphomaActive, not recruiting

Uterine LeiomyosarcomaPhase 2

Active, not recruiting

LeiomyosarcomaPhase 3

Active, not recruiting

LymphomaApproved

Approved

Cutaneous MelanomaPhase 3

Active, not recruiting

Pancreatic Neuroendocrine TumorApproved

Approved

Metastatic MelanomaPhase 3

Active, not recruiting

Hodgkins LymphomaApproved

Active, not recruiting

NeuroblastomaPhase 3

Active, not recruiting

Uveal MelanomaPhase 3

Active, not recruiting

Classic Hodgkin LymphomaPhase 2

Active, not recruiting

Showing 10 of 20 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Approved

46 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Tafasitamab

Incyte

Preclinical

7 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Lymphoma

NCT03407144

Phase 2Active, not recruiting

Lymphoma

NCT03517137

Phase 3Recruiting

Lymphoma

NCT04638790

Phase 2Active, not recruiting

Lymphoma

NCT04067037

Q1 2027

Phase 1/2Active, not recruiting

Lymphoma

NCT03033914

Phase 3Active, not recruiting

Stage III

NCT03907488

Clinical

Trials by Indication[1]

Lymphoma46 trials

Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00416377·353 enrolled

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT01868451·118 enrolled

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

Not yet recruiting·—·Phase 2·NCT07275216·23 enrolled

Show 43 more trials

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01390584·6 enrolled

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06377566·71 enrolled

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05008224·146 enrolled

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT01569204·100 enrolled

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Completed· Pfizer logo

Pfizer·Phase 2·NCT01716806·131 enrolled

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Recruiting·SState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia·Phase 3·NCT04638790·300 enrolled

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT03407144·340 enrolled

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Unknown status·NNorthwestern University·Phase 2·NCT01476410·48 enrolled

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Recruiting·UUniversity of Virginia·Phase 2·NCT05404945·44 enrolled

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01132807·164 enrolled

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT03646123·255 enrolled

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01771107·41 enrolled

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Completed· Takeda logo

Takeda·Phase 3·NCT01712490·1,334 enrolled

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Completed·UUniversity of Washington·Phase 1/2·NCT03331341·50 enrolled

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Completed·CChristine Mauz-Körholz·Phase 3·NCT00433459·2,134 enrolled

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03517137·150 enrolled

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00822120·371 enrolled

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Recruiting· Takeda logo

Takeda·Phase 4·NCT06831370·124 enrolled

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03033914·82 enrolled

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

Unknown status·NNorthwestern University·Phase 2·NCT03226249·30 enrolled

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02292979·170 enrolled

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

Recruiting·UUniversity of Miami·Phase 2·NCT07002216·48 enrolled

Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025064·260 enrolled

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT03004833·110 enrolled

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Completed·UUniversity College, London·Phase 3·NCT00678327·1,202 enrolled

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Unknown status·—·Phase 2·NCT06201507·44 enrolled

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT02505269·34 enrolled

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Active, not recruiting·—·Phase 2·NCT03233347·82 enrolled

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Active, not recruiting· Takeda logo

Takeda·Phase 1/2·NCT02979522·59 enrolled

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01920932·77 enrolled

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02181738·294 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00049595·552 enrolled

Prospective Study on HIV-related Hodgkin Lymphoma

Unknown status·HHarlachinger Krebshilfe e.V.·Phase 2·NCT01468740·130 enrolled

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 1·NCT01060904·51 enrolled

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Terminated·FFrench Innovative Leukemia Organisation·Phase 3·NCT00920153·442 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

Completed·CChristine Mauz-Körholz·Phase 2·NCT00416832·648 enrolled

Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma

Unknown status·MMount Vernon Cancer Centre at Mount Vernon Hospital·Phase 3·NCT00041210·850 enrolled

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003389·854 enrolled

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Active, not recruiting·HHenan Cancer Hospital·Phase 2·NCT04067037·60 enrolled

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

Unknown status·KKing Abdullah International Medical Research Center·Phase 2·NCT03527628·220 enrolled

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00369681·51 enrolled

Melanoma31 trials

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT01152788·64 enrolled

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Completed·—·Phase 1·NCT00498979·22 enrolled

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Completed·CCentocor, Inc.·Phase 1/2·NCT00246012·144 enrolled

Show 28 more trials

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01721746·405 enrolled

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

Terminated·AAmerican Regent, Inc.·Phase 3·NCT00087776·393 enrolled

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Completed·GGenta Incorporated·Phase 3·NCT00016263

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01704287·540 enrolled

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02545075·182 enrolled

A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients

Unknown status·OOrienGene Biotechnology Ltd.·Phase 2·NCT04200040·165 enrolled

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00324155·681 enrolled

PTK/ZK in Disseminated Malignant Melanoma

Terminated·MMichael Weichenthal·Phase 1/2·NCT00615160·9 enrolled

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

Completed·VVical·Phase 3·NCT00395070·390 enrolled

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Completed· GSK logo

GSK·Phase 3·NCT01227889·251 enrolled

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Completed· Bayer logo

Bayer·Phase 2·NCT00110994·101 enrolled

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00936221·385 enrolled

Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma

Terminated·NN.N. Petrov National Medical Research Center of Oncology·Phase 2·NCT02190838·57 enrolled

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Completed·VVical·Phase 3·NCT00003647

CPG 7909 Injection in Melanoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT00070642·184 enrolled

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Terminated·AAB Science·Phase 3·NCT01280565·134 enrolled

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Active, not recruiting·EErasca, Inc.·Phase 3·NCT06346067·78 enrolled

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

Completed·NNational Cancer Institute, Naples·Phase 3·NCT01359956·269 enrolled

Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01681212·21 enrolled

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00006237·432 enrolled

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00533702·106 enrolled

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Completed· Eisai logo

Eisai·Phase 1/2·NCT01133977·97 enrolled

Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00072124

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

Unknown status·JJonsson Comprehensive Cancer Center·N/A·NCT00070343

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00864253·529 enrolled

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Completed· Pfizer logo

Pfizer·Phase 3·NCT01763164·402 enrolled

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002882·140 enrolled

Protocol of Clinical Trial of EAFO 2012: Adjuvant Therapy of Skin Melanoma With Use of Alpha Interferon and Naderin

Completed·MMIPO Clinic·Phase 2·NCT07671495·278 enrolled

Metastatic Melanoma17 trials

Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00002669·90 enrolled

A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

Terminated· GSK logo

GSK·Phase 2·NCT00849875·48 enrolled

Dacarbazine and Carmustine in Metastatic Melanoma

Terminated·WWestern Regional Medical Center·Phase 2·NCT01692691·1 enrolled

Show 14 more trials

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Completed· Roche logo

Roche·Phase 3·NCT01006980·675 enrolled

Thalidomide and Dacarbazine for Metastatic Melanoma

Unknown status·NNational Center for Research Resources (NCRR)·Phase 2·NCT00006200

Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00091572·859 enrolled

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Terminated·HHaukeland University Hospital·Phase 2·NCT01705392·2 enrolled

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01721772·418 enrolled

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

Completed·UUniversity of Turku·Phase 2·NCT00308607·27 enrolled

A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

Completed· Roche logo

Roche·Phase 2·NCT01164007·40 enrolled

Metronomic Therapy in Patients With Metastatic Melanoma

Terminated·—·Phase 2·NCT01542255·7 enrolled

Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00412581·28 enrolled

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

Completed·UUniversity of Chicago·Phase 2·NCT00004141·46 enrolled

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Terminated·PPhilogen S.p.A.·Phase 2·NCT01055522·102 enrolled

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835145·47 enrolled

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01143402·120 enrolled

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003027·482 enrolled

Neuroblastoma5 trials

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Completed·—·Phase 3·NCT00002802·500 enrolled

Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Completed·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 2·NCT00017225

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT04221035·800 enrolled

Show 2 more trials

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·N/A·NCT00526318·360 enrolled

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 3·NCT00410631·642 enrolled

Hodgkin's Disease5 trials

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01404936·35 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 2·NCT00004010·99 enrolled

Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002561·405 enrolled

Show 2 more trials

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease

Completed·MMedical Research Council·Phase 3·NCT00003421·800 enrolled

Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000626·27 enrolled

23 more indications

Uveal Melanoma5 trials

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01974752·152 enrolled

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Active, not recruiting·IIDEAYA Biosciences·Phase 2/3·NCT05987332·420 enrolled

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Completed·—·Phase 2·NCT01100528·38 enrolled

Show 2 more trials

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Completed·IImmunocore Ltd·Phase 2·NCT03070392·378 enrolled

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

Completed·TThe Clatterbridge Cancer Centre NHS Foundation Trust·Phase 2·NCT01551459·124 enrolled

Classic Hodgkin Lymphoma5 trials

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00654732·58 enrolled

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05922904·25 enrolled

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Active, not recruiting·—·Phase 2·NCT03712202·155 enrolled

Show 2 more trials

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Recruiting·NNational Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT06984146·54 enrolled

A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients.

Active, not recruiting·NNorthwestern University·Phase 2·NCT06164275·30 enrolled

Soft Tissue Sarcoma4 trials

Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00002791

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00089544·23 enrolled

Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)

Recruiting·SSwiss Cancer Institute·Phase 2·NCT06835049·24 enrolled

Show 1 more trial

Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1/2·NCT00023738

Leiomyosarcoma4 trials

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Completed·PPTC Therapeutics·Phase 1·NCT03761095·41 enrolled

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Terminated·PPTC Therapeutics·Phase 2/3·NCT05269355·359 enrolled

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01343277·579 enrolled

Show 1 more trial

A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01692678·16 enrolled

Dacarbazine2 trials

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00516802·40 enrolled

A Phase I/II Study of Sunitinib and Dacarbazine

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00496223·11 enrolled

Cutaneous Melanoma2 trials

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Completed· EMD Serono logo

EMD Serono·Phase 2·NCT01693068·194 enrolled

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting·IImmatics US, Inc.·Phase 3·NCT06743126·360 enrolled

Bone Sarcoma2 trials

Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma

Completed·WWashington University School of Medicine·Phase 2·NCT00802880·80 enrolled

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT03277924·197 enrolled

Hodgkin Lymphoma2 trials

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05675410·1,875 enrolled

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Recruiting·UUniversity College, London·Phase 3·NCT04685616·1,042 enrolled

Solitary Fibrous Tumor1 trial

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Completed·IItalian Sarcoma Group·Phase 2·NCT03023124·23 enrolled

Tics1 trial

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT00600496·140 enrolled

Brentuximab Vedotin1 trial

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Recruiting·CChildren's Cancer Group, China·Phase 2/3·NCT06563245·96 enrolled

Metastatic Soft-tissue Sarcoma1 trial

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Active, not recruiting·PPhilogen S.p.A.·Phase 2·NCT04733183·98 enrolled

Alveolar Soft Part Sarcoma1 trial

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Recruiting·AAdvenchen Laboratories, LLC·Phase 3·NCT03016819·325 enrolled

Temozolomide1 trial

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00257205·655 enrolled

Advanced Stage1 trial

HD21 for Advanced Stages

Active, not recruiting·UUniversity of Cologne·Phase 3·NCT02661503·1,500 enrolled

Tumor Microenvironment1 trial

Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 2·NCT04225390·38 enrolled

Stem Cell Transplantation1 trial

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00005090·11 enrolled

Interaction1 trial

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00796991·72 enrolled

Chemotherapy1 trial

Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus

Terminated·GGynecologic Oncology Group·Phase 2·NCT00033644

Advanced Hodgkin Lymphoma1 trial

A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma

Recruiting·UUniversity of Washington·Phase 2·NCT06745076·125 enrolled

Stage III1 trial

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03907488·994 enrolled

LMS - Leiomyosarcoma1 trial

Phase 2 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Gemcitabine Followed by Systemic Adjuvant Chemotherapy With Dacarbazine for Locally Recurrent Uterine Leiomyosarcoma (LMS)

Completed·SStanford University·Phase 2·NCT04727242·17 enrolled

Unspecified2 trials

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Completed·FFondazione Italiana Linfomi - ETS·Phase 3·NCT03159897·500 enrolled

Rituximab and ABVD for Hodgkin's Patients

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00504504·85 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DTIC-DOME

NDA NDA017575

Sources

References

[1]
ClinicalTrials.gov — 146 trial records for Dacarbazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — DTIC-Dome drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Dacarbazine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Dacarbazine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA017575). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bayer

DTIC-Dome

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Lymphoma46 trials

Melanoma31 trials

Metastatic Melanoma17 trials

Neuroblastoma5 trials

Hodgkin's Disease5 trials

Uveal Melanoma5 trials

Classic Hodgkin Lymphoma5 trials

Soft Tissue Sarcoma4 trials

Leiomyosarcoma4 trials

Dacarbazine2 trials

Cutaneous Melanoma2 trials

Bone Sarcoma2 trials

Hodgkin Lymphoma2 trials

Solitary Fibrous Tumor1 trial

Tics1 trial

Brentuximab Vedotin1 trial

Metastatic Soft-tissue Sarcoma1 trial

Alveolar Soft Part Sarcoma1 trial

Temozolomide1 trial

Advanced Stage1 trial

Tumor Microenvironment1 trial

Stem Cell Transplantation1 trial

Interaction1 trial

Chemotherapy1 trial

Advanced Hodgkin Lymphoma1 trial

Stage III1 trial

LMS - Leiomyosarcoma1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News